Jason Hill

10PUBLICATIONS
63CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedMolecular targetsAdolescent healthMedical infection agents (incl. prions)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|May 08, 2026
Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

|Mar 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Kohei Shitara, Hirokazu Shoji, Nicola Fazio

|Jul 01, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Mark J Levis, Mehdi Hamadani, Brent R Logan

|Jan 08, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

Mark J Levis, Mehdi Hamadani, Brent R Logan

Pageof 2

Frequent Collaborators

7 joint publications

Mark J Levis

7 joint publications

Alexander E Perl

4 joint publications

Masumi Ueda Oshima

4 joint publications

Lori S Muffly